Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Authors
Lamarca, AngelaPalmer, D.
Wasan, H. S.
Ross, P.
Ma, Y. T.
Arora, A.
Falk, S.
Gillmore, R.
Wadsley, J.
Patel, K.
Anthoney, A.
Maravellas, A.
Waters, J. S. C.
Hoobs, C.
Macdonald, T.
Ryder, D.
Ramage, J.
Davies, L.
Bridgewater, J. A.
Valle, Juan W
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2022
Metadata
Show full item recordCitation
Lamarca A, Palmer D, Wasan HS, Ross P, Ma YT, Arora A, et al. Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology. 2022 Sep;33(7):S564-S5. PubMed PMID: WOS:000866211600054.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.082Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.082Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.082